--- title: "Amicus Therapeutics, Inc. (FOLD.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/FOLD.US.md" symbol: "FOLD.US" name: "Amicus Therapeutics, Inc." industry: "Biotechnology" datetime: "2026-03-14T00:22:27.273Z" locales: - [en](https://longbridge.com/en/quote/FOLD.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/FOLD.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/FOLD.US.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/FOLD.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/FOLD.US.md) # Amicus Therapeutics, Inc. (FOLD.US) ## Company Overview Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [amicusrx.com](https://amicusrx.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-03-13T04:30:16.000Z **Overall: C (0.49)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 79 / 404 | | Industry Median | C | | Industry Average | C | - **Style**: Growth - Stocks whose main business is in the growth stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 20.05% | | | Net Profit YoY | 51.68% | | | P/B Ratio | 16.45 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 4512190231.44 | | | Revenue | 634210000.00 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -11.58% | D | | Profit Margin | -4.27% | D | | Gross Margin | 88.50% | A | | Revenue YoY | 20.05% | B | | Net Profit YoY | 51.68% | B | | Total Assets YoY | 21.00% | A | | Net Assets YoY | 41.33% | A | | Cash Flow Margin | -2339.40% | E | | OCF YoY | 20.05% | B | | Turnover | 0.73 | B | | Gearing Ratio | 71.13% | D | ```chart-data:radar { "title": "Longbridge Financial Score - Amicus Therapeutics, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "20.05%", "rating": "" }, { "name": "Net Profit YoY", "value": "51.68%", "rating": "" }, { "name": "P/B Ratio", "value": "16.45", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "4512190231.44", "rating": "" }, { "name": "Revenue", "value": "634210000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-11.58%", "rating": "D" }, { "name": "Profit Margin", "value": "-4.27%", "rating": "D" }, { "name": "Gross Margin", "value": "88.50%", "rating": "A" }, { "name": "Revenue YoY", "value": "20.05%", "rating": "B" }, { "name": "Net Profit YoY", "value": "51.68%", "rating": "B" }, { "name": "Total Assets YoY", "value": "21.00%", "rating": "A" }, { "name": "Net Assets YoY", "value": "41.33%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "-2339.40%", "rating": "E" }, { "name": "OCF YoY", "value": "20.05%", "rating": "B" }, { "name": "Turnover", "value": "0.73", "rating": "B" }, { "name": "Gearing Ratio", "value": "71.13%", "rating": "D" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -166.44 | 552/404 | - | - | - | | PB | 16.45 | 398/404 | 16.44 | 12.31 | 9.93 | | PS (TTM) | 7.11 | 141/404 | 7.11 | 4.45 | 3.54 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A | | 03 | MiMedx (MDXG.US) | A | B | A | B | B | A | | 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-23T05:00:00.000Z Total Analysts: **7** | Rating | Count | Percentage | |--------|-------|-----------| | Hold | 7 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 14.37 | | Highest Target | 14.50 | | Lowest Target | 14.50 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/FOLD.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/FOLD.US/norm.md) - [Related News](https://longbridge.com/en/quote/FOLD.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/FOLD.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**